ASC Stock Overview
Ascendis Health Limited, a health and wellness company, manufactures and distributes healthcare products in South Africa, Cyprus, Spain, Romania.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Ascendis Health Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | R0.80 |
| 52 Week High | R0.83 |
| 52 Week Low | R0.59 |
| Beta | 0.54 |
| 1 Month Change | -1.23% |
| 3 Month Change | 1.27% |
| 1 Year Change | 29.03% |
| 3 Year Change | 33.33% |
| 5 Year Change | -82.22% |
| Change since IPO | -92.79% |
Recent News & Updates
Shareholder Returns
| ASC | ZA Pharmaceuticals | ZA Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | -0.4% |
| 1Y | 29.0% | 11.2% | -5.8% |
Price Volatility
| ASC volatility | |
|---|---|
| ASC Average Weekly Movement | 2.5% |
| Pharmaceuticals Industry Average Movement | 3.9% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in ZA Market | 11.7% |
| 10% least volatile stocks in ZA Market | 2.8% |
Volatility Over Time: ASC's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 14 | A. Neethling | www.ascendishealth.com |
Ascendis Health Limited, a health and wellness company, manufactures and distributes healthcare products in South Africa, Cyprus, Spain, Romania. It operates through Consumer Health, Pharma, and Medical Devices segments. The company offers natural supplements, multi-vitamin and mineral supplements, micronutrient supplements, nutraceutical supplements, vitamins, minerals, and homeopathic and herbal products under the Bettaway, Chela-Fer, Chela Preg, Chela Mag, Compounding Pharmacy, Junglevites, Menacal 7, Solal, and Vitaforce brand names.
Ascendis Health Limited Fundamentals Summary
| ASC fundamental statistics | |
|---|---|
| Market cap | R500.84m |
| Earnings (TTM) | -R50.51m |
| Revenue (TTM) | R1.50b |
0.3x
P/S Ratio-9.9x
P/E RatioIs ASC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASC income statement (TTM) | |
|---|---|
| Revenue | R1.50b |
| Cost of Revenue | R849.46m |
| Gross Profit | R646.32m |
| Other Expenses | R696.83m |
| Earnings | -R50.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.081 |
| Gross Margin | 43.21% |
| Net Profit Margin | -3.38% |
| Debt/Equity Ratio | 4.4% |
How did ASC perform over the long term?
See historical performance and comparison